Global cancer partnership
Global cancer partnership
Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results
Survival outcomes from the CALGB 40603 study in triple-negative breast cancer
Molecular evolution of breast cancer during neoadjuvant chemotherapy
NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
Editor's choice for December 2015
Novel estrogen receptor-targeting agent represents ‘quantum leap’
Higher local recurrence after skin-sparing than simple mastectomy for DCIS